APG808 resulted in a rapid and durable decrease from baseline in FeNO and pSTAT6 measurements throughout the 12 weeks.

The inclusion of BATURA study results in the US prescribing information builds upon the previous MANDALA Phase III trial in adult patients with moderate to severe asthma. 3 The MANDALA and BATURA ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Questions remain on whether there are links between patients with asthma and RA, including heterogeneity of disease.

In many patients, annual short-acting beta2-agonist prescription fulfillment is indicative of uncontrolled disease and increased incidence of exacerbations. Credit: Getty Images. Short-acting beta ...

If you are wheezing, coughing, or having extreme shortness of breath, you may be having an asthma attack.

ATS 2024, San Diego – Only 14.5 percent of adult patients with moderate or severe asthma are prescribed the recommended SMART combination inhaler regimen and over 40 percent of academic pulmonary and ...

AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma.1 The BATURA Phase IIIb trial, which evaluated severe exacerbation ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

Posters presented at ACAAI 2023 Annual Scientific Congress examined dupilumab use in children with moderate-to-severe asthma and in the presence of elevated type 2 biomarkers. Two posters presented at ...

People with severe asthma may not respond to the usual treatment. Researchers have examined what drives the inflammatory response in severe asthmatics at a molecular level and their findings may lead ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab significantly reduced exacerbations and improved lung function among patients with type 2 biomarkers ...